Results 31 to 40 of about 105,425 (257)

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives

open access: yesExperimental Hematology & Oncology
Histone deacetylase inhibitors (HDACis) are a significant category of pharmaceuticals that have developed in the past two decades to treat multiple myeloma. Four drugs in this category have received approval from the U.S.
Jingjing Pu   +6 more
doaj   +1 more source

Histone acetylation modifiers in the pathogenesis of Alzheimer’s disease

open access: yesFrontiers in Cellular Neuroscience, 2015
It is becoming more evident that histone acetylation, as one of the epigenetic modifications or markers, plays a key role in the etiology of Alzheimer’s disease (AD).
Xi eLu   +4 more
doaj   +1 more source

Phosphoinositides and inositol phosphates as molecular glues

open access: yesFEBS Letters, EarlyView.
Inositol phosphates (IPs) and phosphoinositides (PIPs) regulate diverse eukaryotic processes. Beyond recruiting signaling proteins or acting as structural cofactors, recent studies suggest they mediate protein–protein interactions as natural molecular glues.
Aleshia Seaton‐Terry   +9 more
wiley   +1 more source

Repressing iron overload ameliorates central post-stroke pain via the Hdac2-Kv1.2 axis in a rat model of hemorrhagic stroke

open access: yesNeural Regeneration Research
Thalamic hemorrhage can lead to the development of central post-stroke pain. Changes in histone acetylation levels, which are regulated by histone deacetylases, affect the excitability of neurons surrounding the hemorrhagic area.
He Fang   +8 more
doaj   +1 more source

Design, Synthesis and Cytotoxicity Study of Primary Amides as Histone Deacetylase Inhibitors

open access: yesIraqi Journal of Pharmaceutical Sciences, 2019
Primary amide derivatives as histone deacetylase inhibitors (HDACIs) are very rare. This paper describes the synthesis of primary amide derivatives (compounds 6 and 7) that have the requirements to be histone deacetylase inhibitors of the zinc-binding ...
Duraid Al-Amily, Mohammed H. Mohammed
doaj   +1 more source

From tumor‐centric to ecosystem‐based hypotheses in brain tumor research and care

open access: yesMolecular Oncology, EarlyView.
Primary brain tumors, whether in adults or children, present a major challenge because of their dramatic prognosis and the ongoing lack of efficient therapeutic approaches. In recent years, a shift has occurred from tumor‐centric concepts to a more holistic view of these tumors as dynamic ecosystems.
Julie Gavard   +8 more
wiley   +1 more source

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma

open access: yesFrontiers in Oncology, 2023
This review aims to summarize the putative role of histone deacetylases (HDACs) in rhabdomyosarcoma (RMS) and the effects of HDAC inhibitors (HDACi) on RMS by elucidating and highlighting known oncogenic pathways, mechanisms of resistance, and the ...
Omar Selim   +7 more
doaj   +1 more source

Targeting transcription factors associated with hemoglobinopathies: Lessons from successful interventions and implications for cancer

open access: yesMolecular Oncology, EarlyView.
This review summarizes the transcription factors, repressive chromatin‐modifying complexes, and epigenetic mechanisms that control fetal hemoglobin repression. Notably, many regulators of γ‐globin silencing also function in transcriptional and epigenetic networks that drive cancer, highlighting opportunities to translate advances in hemoglobinopathy ...
Meigen Yu   +3 more
wiley   +1 more source

HDAC inhibitors: A novel approach to hyperglycaemia management and treatment

open access: yesHealth Sciences Review, 2023
The field of genomics plays a prominent role in treatment of numerous chronic diseases. Diabetes is a persistent metabolic disorder. Current studies and reports have emphasised the importance of several epigenetic markers in the therapy of type 2 ...
M. Suchitra   +4 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy